Bayesian estimation of mycophenolate mofetil in lung transplantation, using a population pharmacokinetic model developed in kidney and lung transplant recipients

Clinical Pharmacokinetics

Volumn 51, Issue 1, 2012, Pages 29-39

  De Winter, Brenda C M ^a   Monchaud, Caroline ^a   Prémaud, Aurélie ^a   Pison, Christophe ^b   Kessler, Romain ^c   Reynaud Gaubert, Martine ^d   Dromer, Claire ^e   Stern, Marc ^f   Guillemain, Romain ^g   Knoop, Christiane ^h   Estenne, Marc ^h   Marquet, Pierre ^a   Rousseau, Annick ^a  

^a UNIVERSITY OF LIMOGES   (France)

^b INSERM   (France)

^c HÔPITAL CIVIL   (France)

^d HÔPITAL NORD   (France)

^e HAUT LÉVÊQUE HOSPITAL   (France)

^f FOCH HOSPITAL   (France)

^g HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^h ERASME HOSPITAL   (Belgium)

Author keywords

Dose prediction; Lung transplant; Mycophenolate mofetil; Mycophenolic acid; Pharmacokinetic modelling; Population pharmacokinetics; Renal transplant

Indexed keywords

CREATININE; CYCLOSPORIN A; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; TACROLIMUS;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BAYES THEOREM; CREATININE CLEARANCE; CYSTIC FIBROSIS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG ELIMINATION; FEMALE; GRAFT RECIPIENT; HUMAN; KIDNEY TRANSPLANTATION; LUNG TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL;

ADOLESCENT; ADULT; AGED; AREA UNDER CURVE; BAYES THEOREM; BIOLOGICAL AVAILABILITY; CYSTIC FIBROSIS; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; LUNG TRANSPLANTATION; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; MYCOPHENOLIC ACID; REPRODUCIBILITY OF RESULTS; YOUNG ADULT;

EID: 83455229590     PISSN: 03125963     EISSN: 11791926     Source Type: Journal    
DOI: 10.2165/11594050-000000000-00000     Document Type: Article

References (45)

1. Knoll G. Trends in kidney transplantation over the past decade. Drugs 2008; 68 Suppl. 1: 3-10 (Pubitemid 351601432)
2. Allison AC, Eugui EM. Purine metabolism and immunosuppressive effects of mycophenolate mofetil (MMF). Clin Transplant 1996; 10 (1 Pt 2): 77-84 (Pubitemid 26076435)
3. Bullingham RE, Nicholls AJ, Kamm BR. Clinical pharmacokinetics of mycophenolate mofetil. Clin Pharmacokinet 1998; 34 (6): 429-55 (Pubitemid 28273453)
4. de Winter BC, van Gelder T. Therapeutic drug monitoring for mycophenolic acid in patients with autoimmune diseases. Nephrol Dial Transplant 2008; 23 (11): 3386-8
5. Le Meur Y, Buchler M, Thierry A, et al. Individualized mycophenolate mofetil dosing based on drug exposure significantly improves patient outcomes after renal transplantation. Am J Transplant 2007; 7 (11): 2496-503 (Pubitemid 47566324)
6. van Gelder T, Silva HT, de Fijter JW, et al. Comparing mycophenolate mofetil regimens for de novo renal transplant recipients: the fixed-dose concentration-controlled trial. Transplantation 2008; 86 (8): 1043-51
7. Shaw LM, Holt DW, Oellerich M, et al. Current issues in therapeutic drug monitoring of mycophenolic acid: report of a roundtable discussion. Ther Drug Monit 2001; 23 (4): 305-15 (Pubitemid 32708913)
8. Premaud A, Le Meur Y, Debord J, et al. Maximum a posteriori Bayesian estimation of mycophenolic acid pharmacokinetics in renal transplant recipients at different postgrafting periods. Ther Drug Monit 2005; 27 (3): 354-61 (Pubitemid 40770993)
9. Le Guellec C, Bourgoin H, Buchler M, et al. Population pharmacokinetics and Bayesian estimation of mycophenolic acid concentrations in stable renal transplant patients. Clin Pharmacokinet 2004; 43 (4): 253-66 (Pubitemid 38429305)
10. Trulock EP, Christie JD, Edwards LB, et al. Registry of the International Society for Heart and Lung Transplantation: twenty-fourth official adult lung and heart-lung transplantation report-2007. J Heart Lung Transplant 2007; 26 (8): 782-95 (Pubitemid 47199080)
11. Knoop C, Haverich A, Fischer S. Immunosuppressive therapy after human lung transplantation. Eur Respir J 2004; 23 (1): 159-71 (Pubitemid 38088513)
12. Snell GI, Westall GP. Immunosuppression for lung transplantation: evidence to date. Drugs 2007; 67 (11): 1531-9 (Pubitemid 47267296)
13. Jaksch P, Kocher A, Neuhauser P, et al. Monitoring C2 level predicts exposure in maintenance lung transplant patients receiving the microemulsion formulation of cyclosporine (Neoral). J Heart Lung Transplant 2005; 24 (8): 1076-80 (Pubitemid 41127190)
14. Gerbase MW, Fathi M, Spiliopoulos A, et al. Pharmacokinetics of mycophenolic acid associated with calcineurin inhibitors: long-term monitoring in stable lung recipients with and without cystic fibrosis. J Heart Lung Transplant 2003; 22 (5): 587-90 (Pubitemid 36549060)
15. de Winter BC, van Gelder T, Sombogaard F, et al. Pharmacokinetic role of protein binding of mycophenolic acid and its glucuronide metabolite in renal transplant recipients. J Pharmacokinet Pharmacodyn 2009; 36: 541-64
16. Monchaud C, Marquet P. Pharmacokinetic optimization of immunosuppressive therapy in thoracic transplantation: part II. Clin Pharmacokinet 2009; 48 (8): 489-516
17. Ting LS, Partovi N, Levy RD, et al. Limited sampling strategy for predicting area under the concentration-time curve of mycophenolic acid in adult lung transplant recipients. Pharmacotherapy 2006; 26 (9): 1232-40 (Pubitemid 44306882)
18. de Winter BC, Mathot RA, van Hest RM, et al. Therapeutic drug monitoring of mycophenolic acid: does it improve patient outcome? Expert Opin Drug Metab Toxicol 2007; 3 (2): 251-61 (Pubitemid 47316040)
19. Le Guellec C, Buchler M, Giraudeau B, et al. Simultaneous estimation of cyclosporin and mycophenolic acid areas under the curve in stable renal transplant patients using a limited sampling strategy. Eur J Clin Pharmacol 2002; 57 (11): 805-11 (Pubitemid 34143339)
20. Premaud A, Debord J, Rousseau A, et al. A double absorption-phase model adequately describes mycophenolic acid plasma profiles in de novo renal transplant recipients given oral mycophenolate mofetil. Clin Pharmacokinet 2005; 44 (8): 837-47 (Pubitemid 41126931)
21. Buchler M, Caillard S, Barbier S, et al. Sirolimus versus cyclosporine in kidney recipients receiving thymoglobulin, mycophenolate mofetil and a 6-month course of steroids. Am J Transplant 2007; 7 (11): 2522-31 (Pubitemid 47561618)
22. Benkali K, Premaud A, Picard N, et al. Tacrolimus population pharmacokinetic-pharmacogenetic analysis and Bayesian estimation in renal transplant recipients. Clin Pharmacokinet 2009; 48 (12): 805-16
23. Djebli N, Picard N, Rerolle JP, et al. Influence of theUGT2B7 promoter region and exon 2 polymorphisms and comedications on Acyl-MPAG production in vitro and in adult renal transplant patients. Pharmacogenet Genomics 2007; 17 (5): 321-30 (Pubitemid 46608539)
24. Djebli N, Rousseau A, Hoizey G, et al. Sirolimus population pharmacokinetic/pharmacogenetic analysis and Bayesian modelling in kidney transplant recipients. Clin Pharmacokinet 2006; 45 (11): 1135-48 (Pubitemid 44631392)
25. Monchaud C, Pison C, Reynaud-Gaubert M, et al. New tools for mycophenolate mofetil (MMF) dose optimization in lung transplant recipients during the first year post-transplantation: the STIMMUGREP trial [abstract]. J Heart Lung Transplant 2011; 30 (4) Suppl.: S74
26. Premaud A, Rousseau A, Picard N, et al. Determination of mycophenolic acid plasma levels in renal transplant recipients co-administered sirolimus: comparison of an enzyme multiplied immunoassay technique (EMIT) and liquid chromatography-tandem mass spectrometry. Ther Drug Monit 2006; 28 (2): 274-7 (Pubitemid 44314962)
27. Wahlby U, Jonsson EN, Karlsson MO. Comparison of stepwise covariate model building strategies in population pharmacokinetic-pharmacodynamic analysis. AAPS PharmSci 2002; 4 (4): E27
28. Ette EI, Williams PJ, Kim YH, et al. Model appropriateness and population pharmacokinetic modeling. J Clin Pharmacol 2003; 43 (6): 610-23 (Pubitemid 36613120)
29. Jadhav PR, Gobburu JV. A new equivalence based metric for predictive check to qualify mixed-effects models. AAPS J 2005; 7 (3): E523-31
30. Rousseau A, Leger F, Le Meur Y, et al. Population pharmacokinetic modeling of oral cyclosporin using NONMEM: comparison of absorption pharmacokinetic models and design of a Bayesian estimator. Ther Drug Monit 2004; 26 (1): 23-30 (Pubitemid 38140906)
31. Frame B, Miller R, Lalonde RL. Evaluation of mixture modeling with count data using NONMEM. J Pharmacokinet Pharmacodyn 2003; 30 (3): 167-83 (Pubitemid 37176044)
32. de Winter BC, van Gelder T, Glander P, et al. Population pharmacokinetics of mycophenolic acid: a comparison between enteric-coated mycophenolate sodium and mycophenolate mofetil in renal transplant recipients. Clin Pharmacokinet 2008; 47 (12): 827-38
33. Lee PI. Design and power of a population pharmacokinetic study. Pharm Res 2001; 18 (1): 75-82 (Pubitemid 32299625)
34. Musuamba FT, Rousseau A, Bosmans JL, et al. Limited sampling models and Bayesian estimation for mycophenolic acid area under the curve prediction in stable renal transplant patients co-medicated with ciclosporin or sirolimus. Clin Pharmacokinet 2009; 48 (11): 745-58
35. Shum B, Duffull SB, Taylor PJ, et al. Population pharmacokinetic analysis of mycophenolic acid in renal transplant recipients following oral administration of mycophenolate mofetil. Br J Clin Pharmacol 2003; 56 (2): 188-97 (Pubitemid 36981434)
36. van Hest RM, van Gelder T, Vulto AG, et al. Population pharmacokinetics of mycophenolic acid in renal transplant recipients. Clin Pharmacokinet 2005; 44 (10): 1083-96 (Pubitemid 41356393)
37. van Hest RM, Mathot RA, Pescovitz MD, et al. Explaining variability in mycophenolic acid exposure to optimize mycophenolate mofetil dosing: a population pharmacokinetic meta-analysis of mycophenolic acid in renal transplant recipients. J Am Soc Nephrol 2006; 17 (3): 871-80
38. deWinter BC,MathotRA, Sombogaard F, et al.Nonlinear relationship between mycophenolate mofetil dose and mycophenolic acid exposure: implications for therapeutic drug monitoring. Clin J Am Soc Nephrol 2011; 6 (3): 656-63
39. Sherwin CM, Fukuda T, Brunner HI, et al. The evolution of population pharmacokinetic models to describe the enterohepatic recycling of mycophenolic acid in solid organ transplantation and autoimmune disease. Clin Pharmacokinet 2011; 50 (1): 1-24
40. Wahlby U, Jonsson EN, Karlsson MO. Assessment of actual significance levels for covariate effects inNONMEM.JPharmacokinet Pharmacodyn 2001; 28 (3): 231-52 (Pubitemid 32643366)
41. Hesselink DA, van Hest RM, Mathot RA, et al. Cyclosporine interacts with mycophenolic acid by inhibiting the multidrug resistance-associated protein. Am J Transplant 2005; 5 (5): 987-94 (Pubitemid 40571246)
42. Picard N, Yee SW, Woillard JB, et al. The role of organic anion-transporting polypeptides and their common genetic variants in mycophenolic acid pharmacokinetics. Clin Pharmacol Ther 2010; 87 (1): 100-8
43. Saint-Marcoux F, Knoop C, Debord J, et al. Pharmacokinetic study of tacrolimus in cystic fibrosis and non-cystic fibrosis lung transplant patients and design of Bayesian estimators using limited sampling strategies. Clin Pharmacokinet 2005; 44 (12): 1317-28 (Pubitemid 41832572)
44. Ting LS, Partovi N, Levy RD, et al. Pharmacokinetics of mycophenolic acid and its phenolic-glucuronide and ACYl glucuronide metabolites in stable thoracic transplant recipients. Ther Drug Monit 2008; 30 (3): 282-91
45. de Winter BC, Neumann I, van Hest RM, et al. Limited sampling strategies for therapeutic drug monitoring of mycophenolate mofetil therapy in patients with autoimmune disease. Ther Drug Monit 2009; 31 (3): 382-90